转移性去势抵抗性前列腺癌循环肿瘤细胞AR-V7状态与细胞计数及生存的关联
该研究基于三项前瞻性临床试验,纳入127例多西他赛和/或恩杂鲁胺或阿比特龙治疗后进展的mCRPC患者,检测基线及随访时循环肿瘤细胞(CTC)计数和AR-V7表达,多数患者后续接受卡巴他赛治疗。结果显示AR-V7与CTC计数在总体人群相关(p=0.017),但在≥5 CTCs的预后不良亚组中无关联;校正临床预后因素后,AR-V7表达与总生存无关(HR=1.33,95%CI 0.81-2.15,p=0.25)。
要点
- 在总体mCRPC患者中AR-V7与CTC计数相关(p=0.017),但≥5 CTCs亚组无此关联。
- 校正临床预后因素后,CTC中AR-V7表达与总生存无关(HR=1.33,95%CI 0.81-2.15,p=0.25)。
- 对于CTC≥5的预后不良患者,亟需预测性生物标志物指导治疗选择。
核心结论
- 在多数接受卡巴他赛治疗的mCRPC患者中,CTC中AR-V7表达未显示额外预后价值。
研究设计与样本
- 研究基于2011年12月至2019年1月三项前瞻性临床试验,收集多西他赛和/或恩杂鲁胺或阿比特龙治疗后进展的mCRPC患者临床数据。
- 检测基线及随访血液样本的CTC计数和AR-V7表达,共127个样本可评估CTC计数与AR-V7状态的关系。
主要发现
- 在全部mCRPC患者中观察到AR-V7与CTC计数相关(p=0.017)。
- 在≥5 CTCs的预后不良亚组中未发现AR-V7与CTC计数的关联。
- 校正临床预后因素后,CTC中AR-V7表达与总生存无关(HR=1.33,95%CI 0.81-2.15,p=0.25)。
临床怎么用
- 对于mCRPC患者,尤其是CTC≥5的预后不良人群,AR-V7检测暂不能作为常规预后分层依据。
- 前瞻性试验应探索CTC中AR-V7检测能否指导预后不良患者的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interpretation of the presence of AR-V7 in circulating tumour cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) remains to be elucidated. AR-V7 may hold promise as a predictive biomarker, but there may be prognostic impact of AR-V7 positivity as well. To investigate the clinical value of AR-V7, we determined whether AR-V7 detection in CTCs in patients with mCRPC is associated with CTC counts and survival. METHODS: Between December 2011 and January 2019, three prospective clinical trials collected clinical data of patients with mCRPC, who progressed after docetaxel and/or enzalutamide or abiraterone. Baseline (and follow-up) blood samples were withdrawn determining CTC count and AR-V7 expression. The majority of patients started cabazitaxel as the next line of treatment after AR-V7 characterisation. RESULTS: A total of 127 samples were evaluable for the analysis of CTC count versus AR-V7 status. Although an association was observed between AR-V7 and CTC count in all patients with mCRPC (p = 0.017), no such association was found in the prognostic unfavourable subgroup of patients with ≥5 CTCs. After adjusting for clinical prognostic factors, AR-V7 expression in CTCs was not associated with overall survival (hazard ratio = 1.33, 95% confidence interval = 0.81-2.15, p = 0.25). CONCLUSION: We found that AR-V7 expression in CTCs had no additional prognostic value in patients with mCRPC, mostly treated with cabazitaxel. In patients with mCRPC with a predefined worse prognosis of a higher CTC count (≥5), a predictive biomarker is an important unmet medical need. Prospective trials should investigate whether AR-V7 detection in CTCs may guide treatment selection for these adverse prognosis patients.
引用
- Belderbos BPS, Sieuwerts AM, Hoop EO, et al. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2019. PMID: 31542641. doi:10.1016/j.ejca.2019.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。